ArticleJournal of medicinal chemistry2019
Selective Phenylimidazole-Based Inhibitors of the
Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Identification of Natural Inhibitors against theCurrent drug targets · 2026Article
- Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies.Journal of medicinal chemistry · 2025Review
- Review
- Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.Journal of medicinal chemistry · 2022Article
- Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.Frontiers in cellular and infection microbiology · 2022Review
- Microbial proteasomes as drug targets.PLoS pathogens · 2021Review
- Macrocyclic Peptides that Selectively Inhibit theJournal of medicinal chemistry · 2021Article
- Control of Toxin-Antitoxin Systems by Proteases inFrontiers in molecular biosciences · 2021Review
- Novel Treatments againstAntibiotics (Basel, Switzerland) · 2020Review
- Psoralen Derivatives as Inhibitors ofMolecules (Basel, Switzerland) · 2020Article
- Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.Molecules (Basel, Switzerland) · 2020Review
- Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.Drug design, development and therapy · 2020Review
- The mycobacterial proteasomal ATPase Mpa forms a gapped ring to engage the 20S proteasome.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
Proteasomes of pathogenic microbes have become attractive targets for anti-infectives. Coevolving with its human host,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.